Dolastatin 15 derivatives

US5985837A · kind A · utility

Assignee

• BASF SE

Inventors

• Kurt Ritter · Heidelberg, DE
• Bernd Janssen · Ludwigshafen, DE
• Andreas Haupt · Ludwigshafen, DE
• Andreas Kling · Mannheim, DE
• Teresa Barlozzari · Wellesley, US
• Wilhelm Amberg · Ludwigshafen, DE

Key dates

• Filing date: Jul 8, 1998
• Grant date: Nov 16, 1999
• Expiry date: Jul 8, 2018

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Compounds of the present invention include cell growth inhibitors which are peptides of Formula I EQU A--B--D--E--F--G (I) and acid salts thereof, wherein A, D, and E are .alpha.-amino acid residues, B is an .alpha.-amino acid residue or an .alpha.-hydroxy acid residue, F is an aminobenzoic acid residue or an aminocycloalkanecarboxylic acid residue, and G is a monovalent radical, such as, for example, a hydrogen atom, an amino group, an alkyl group, an alkylene alkyl ether, an alkylene alkyl thioether, an alkylene aldehyde, an alkylene amide, a .beta.-hydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, an oximato group, an alkylene aryl group, an alkylene ester, an alkylene sulfoxide or an alkylene sulfone. Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier. An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable composition.